Opendata, web and dolomites

ADDIA SIGNED

Validation of a fast and simple peripheral blood diagnostic biomarker kit for Alzheimer’s disease

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 ADDIA project word cloud

Explore the words cloud of the ADDIA project. It provides you a very rough idea of what is the project "ADDIA" about.

months    proven    detect    exists    expensive    disease    monitoring    400    single    enrol    economy    proof    blood    patients    flow    organisation    autopsy    committed    alzheimer    diagnostics    previously    combination    procedure    formally    diagnose    cerebrospinal    innovative    risky    healthcare    ad    performance    sme    pop    efficacy    fluid    invasive    usually    successful    tests    french    patient    centres    registered    diagnosed    diagnosis    fluorescent    small    probes    clinical    ready    examination    japan    assay    company    performed    ivd    puncture    weeks    america    validated    lumbar    property    800    annually    ce    imaging    brain    commercialization    urgent    fast    performing    meet    medical    scientifically    inexpensive    consequently    questionable    amounts    intellectual    treatment    cytometry    addia    human       market    validate    neuropsychological    introduction    definite    kit    biomarker    quality    amoneta    biomarkers    initial    diagnostic    life    million    drug    holds    subjects   

Project "ADDIA" data sheet

The following table provides information about the project.

Coordinator
AMONETA DIAGNOSTICS 

Organization address
address: 17 RUE DU FORT
city: HUNINGUE
postcode: 68330
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country France [FR]
 Project website http://www.addia-project-h2020.eu
 Total cost 4˙998˙625 €
 EC max contribution 4˙998˙625 € (100%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-SMEINST-2-2014
 Funding Scheme SME-2
 Starting year 2015
 Duration (year-month-day) from 2015-08-01   to  2019-07-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    AMONETA DIAGNOSTICS FR (HUNINGUE) coordinator 4˙998˙625.00

Map

 Project objective

The French SME Amoneta Diagnostics has previously developed a diagnostic kit for Alzheimer’s disease (AD) based on two blood biomarkers that are scientifically proven to be associated with AD. The company holds the intellectual property for specific fluorescent probes that can detect these biomarkers in small amounts of blood using flow cytometry. Currently, no single test to diagnose AD exists. A potential AD diagnosis is usually given by a combination of clinical examination, neuropsychological tests and brain imaging over weeks/months. A lumbar puncture can be performed to detect biomarkers in cerebrospinal fluid, but this procedure is risky and expensive. A definite AD diagnosis can formally only be given by autopsy. Consequently, the diagnosis is assessed late and still questionable. The novel kit allows the diagnosis of AD, using only one single test, in a fast, non-invasive and inexpensive way. We expect the blood-based biomarker kit to facilitate assessment of drug efficacy in AD drug development and the monitoring of treatment efficacy in AD patients. This kit will meet the urgent medical need of ~2 million patients in Europe, Japan and America, that are annually diagnosed with AD. Successful implementation will have a strong impact on the quality of life of patients and a significant impact on the healthcare system and economy. In this project, Amoneta Diagnostics will validate this diagnostic test by performing a Proof-of-Performance (PoP) clinical study in 800 human subjects including 400 AD patients. At the end of this 3-year project, a validated and CE registered IVD biomarker assay will be available and ready for clinical application. This innovative ADDIA biomarker assay will be ready for initial market introduction and further commercialization and implementation. The project is supported by patient organisation Alzheimer Europe, and several leading European Alzheimer centres that are committed to enrol subjects for the PoP clinical study.

 Deliverables

List of deliverables.
Scientific papers prepared for peer-reviewed open access journals Documents, reports 2019-11-11 10:17:23
Letters and project updates to patient organisation Alzheimer Europe Documents, reports 2019-11-11 10:17:23

Take a look to the deliverables list in detail:  detailed list of ADDIA deliverables.

 Publications

year authors and title journal last update
List of publications.
2018 Bruno Dubois, MD, PhD, Professor, Jean-Christophe Bier, MD, Frederic Blanc, MD, PhD, Renaud David, MD, PhD, Jean-François Démonet, MD, PhD, Hüseyin Firat, MD, PhD, Giovanni B Frisoni, Prof, PhD, MD, Audrey Gabelle, MD, PhD, Hakan I. Gurvit, MD, Adrian Ivanoiu, MD, PhD, Eloi Magnin, MD, PhD, Moira Marizzoni, PhD, Saliha Moussaoui, PhD, Florence Pasquier, MD PhD and François Sellal, MD
Addia, a Multi- Center Clinical Study of Proof-of-Performance to Validate Blood-BasedBiomarkers for the Diagnostic of Alzheimer’s Disease (AD): The Study Protocol.
published pages: , ISSN: , DOI:
2019-08-29
2019 F. Blanc, F. Giovanni, M. Marizzoni, C. Mutter, J.C. Bier, F. Sellal, J.F. Démonet, S. Boutillier, H. Firat, S. Moussaoui, R. David, A. Ivanoiu, E. Magnin, A. Gabelle, F. Pasquier, H. Gurvit, B. Dubois
ADDIA Chronobiology Study and Proof-of-Performance Study to Validate Blood-Based Biomarkers for the Diagnostic of early Alzheimer’s Disease (AD)
published pages: , ISSN: , DOI:
2019-08-29

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "ADDIA" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "ADDIA" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

CLOSER (2019)

Childhood Leukemia: Overcoming distance between South America and Europe Regions

Read More  

GACD (2019)

Global Alliance for Chronic Diseases Secretariat

Read More  

PREFERABLE (2019)

Project on Exercise for Fatigue Eradication in Advanced Breast cancer to improve quality of life

Read More